NASDAQ: EPRXEupraxia Pharmaceuticals Inc Stock
$6.38+0.14 (+2.24%)
Updated Jul 21, 2026
EPRX Price
$6.38
Fair Value Price
$1.43
Market Cap
$394.34M
52 Week Low
$5.01
52 Week High
$9.32
P/E
-6.08x
P/B
2.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$44.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$33M
Beta
0.76
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
EPRX Overview
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EPRX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EPRX
Ranked#449 of 464
Ranked#449 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important EPRX news, forecast changes, insider trades & much more!
EPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EPRX ($6.38) is overvalued by 346.45% relative to our estimate of its Fair Value price of $1.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EPRX ($6.38) is not significantly undervalued (346.45%) relative to our estimate of its Fair Value price of $1.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EPRX due diligence checks available for Premium users.
Valuation
EPRX fair value
Fair Value of EPRX stock based on Discounted Cash Flow (DCF)
Price
$6.38
Fair Value
$1.43
Overvalued by
346.45%
EPRX ($6.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EPRX ($6.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.08x
Industry
21.35x
Market
12.07x
EPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.86x
Industry
5.42x
EPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.7M
Profit Margin
0%
EPRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$145.4M
Liabilities
$9.2M
Debt to equity
0.07
EPRX's short-term assets ($142.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPRX's short-term assets ($142.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.1M
Investing
-$80.1M
Financing
$68.6M
EPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EPRX vs Biotech Stocks
Eupraxia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.